Table 2.
Adjusted HR (95 % CI) for allergy medication, in relation to traffic-related exposure, n = 7898
| Allergy medicationa | ||
|---|---|---|
| Nasal anti-allergics | Oral antihistamine | |
| 1st purchase | 1st purchase | |
| Heaviest road ≤100 m, birth addressb | ||
| 0–8639 cars/day | 1.0 | 1.0 |
| ≥ 8640 | 0.89 (0.61–1.29) | 0.91 (0.83–1.00) |
| Heaviest road ≤100 m, never movedb | ||
| 0–8639 cars/day | 1.0 | 1.0 |
| ≥ 8640 | 0.83 (0.51–1.36) | 0.90 (0.79–1.03) |
| NOX, birth addressc | ||
| ≤ 15 μg/m3 | 1.0 | 1.0 |
| 15–25 | 0.84 (0.58–1.21) | 0.86 (0.77–0.95) |
| > 25 | 0.86 (0.50–1.49) | 0.81 (0.68–0.96) |
| NOX, never movedc | ||
| ≤ 15 μg/m3 | 1.0 | 1.0 |
| 15–25 | 0.95 (0.62–1.47) | 0.88 (0.78–0.99) |
| > 25 | 0.95 (0.42–2.16) | 0.77 (0.62–0.96) |
| NOX, lifetime meand | ||
| ≤ 15 μg/m3 | 1.0 | 1.0 |
| 15–25 | 0.92 (0.62–1.35) | 0.84 (0.75–0.93) |
| > 25 | 0.59 (0.23–1.50) | 0.70 (0.56–0.89) |
aAdjusted for sex, season, parental origin, year of birth, breastfeeding, and parental allergy
b n = 6093 children had complete covariate information and traffic exposure assessments
c n = 6091 children had complete covariate information and modeled NOx concentrations
dThe number of children with complete covariate information and modeled mean NOx during time at risk, was n = 5264 for nasal antiallergics, and n = 5317 for oral antihistamines